RxSight (RXST) Depreciation & Amortization (CF) (2020 - 2026)
RxSight (RXST) posted Depreciation & Amortization (CF) of $834000.0 for Q1 2026, down 2.0% on a QoQ basis from $851000.0 in Q4 2025, and up 7.47% year-over-year from $776000.0 in Q1 2025.
RxSight (RXST) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
RxSight's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $834000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 7.47% year-over-year to $834000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 2.72% YoY) and the FY2025 annual result came in at $3.3 million, down 8.64% from the prior year.
- Depreciation & Amortization (CF) was $834000.0 for Q1 2026 at RxSight, down from $851000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.1 million in Q3 2024 and bottomed at $515000.0 in Q4 2024.
- A 5-year average of $919823.5 and a median of $941000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) sank 51.0% — and 2025, when it surged 65.24%.
- RxSight's Depreciation & Amortization (CF) stood at $918000.0 in 2022, then rose by 14.49% to $1.1 million in 2023, then sank by 51.0% to $515000.0 in 2024, then jumped by 65.24% to $851000.0 in 2025, then decreased by 2.0% to $834000.0 in 2026.
- Business Quant data shows RXST's Depreciation & Amortization (CF) at $834000.0 in Q1 2026, $851000.0 in Q4 2025, and $854000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 381.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 120.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 716.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 351.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 40.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 67.10 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 310.25 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 78.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RxSight | 221.81 Mn | -196.39 Mn | 23.50 Mn | 834,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 834,000.00 |
| Mar 31, 2026 | 834,000.00 |
| Dec 31, 2025 | 851,000.00 |
| Dec 31, 2025 | 851,000.00 |
| Sep 30, 2025 | 854,000.00 |
| Sep 30, 2025 | 854,000.00 |
| Jun 30, 2025 | 785,000.00 |
| Jun 30, 2025 | 785,000.00 |
| Mar 31, 2025 | 776,000.00 |
| Mar 31, 2025 | 776,000.00 |
| Dec 31, 2024 | 515,000.00 |
| Dec 31, 2024 | 515,000.00 |
| Sep 30, 2024 | 1.13 Mn |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 812,000.00 |
| Jun 30, 2024 | 812,000.00 |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Dec 31, 2023 | 1.05 Mn |